Cell cycle effects of topotecan alone and in combination with irradiation

Radiotherapy and Oncology

Volumn 75, Issue 2, 2005, Pages 237-245

  Ohneseit, Petra A ^a   Prager, Daniela ^a   Kehlbach, Rainer ^a   Rodemann, H Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cell cycle; Fibroblasts; Glioblastoma; Ionizing radiation; Topotecan; TP53

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA TOPOISOMERASE INHIBITOR; PROTEIN P53; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENOMICS; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG FIBROBLAST; METAPHASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RADIATION RESPONSE; RADIOSENSITIVITY; TUMOR CELL; WILD TYPE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; LUNG; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20444362353     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2005.03.025     Document Type: Article

References (30)

1. A.Y. Chen, H. Choy, and M.L. Rothenberg DNA topoisomerase I-targeting drugs as radiation sensitizers Oncology (Huntingt) 13 1999 39 46
2. W.A. Cliby, K.A. Lewis, K.K. Lilly, and S.H. Kaufmann S phase and G2 arrest by topoisomerase I poisons are dependent on ATR kinase function J Biol Chem 277 2002 1599 1606
3. R.L. Coleman Emerging role of topotecan in front-line treatment of carcinoma of the ovary Oncologist 7 2002 46 55
4. W.J. Curran, C.B. Scott, and J. Horton Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 1993 704 710
5. G.P. Feeney, R.J. Errington, M. Wiltshire, S.C. Chappel, and P.J. Smith Tracking the cell cycle origins for escape from topotecan action by breast cancer cells Br J Cancer 88 2003 1310 1317
6. J.V. Fiorica Update on the treatment of cervical and uterine carcinoma: focus on topotecan Oncologist 7 2002 36 45
7. B. Fisher, M. Won, D. Macdonald, D.W. Johnson, and W. Roa Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of radiation therapy oncology group 9513 Int J Radiat Oncol Biol Phys 53 2002 980 986
8. C. Gobert, A. Skladanowski, and A.K. Larsen The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53 Proc Natl Acad Sci USA 96 1999 10355 10360
9. F. Goldwasser, T. Shimizu, and J. Jackman Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells Cancer Res 56 1996 4430 4437
10. V. Gottifredi, S.Y. Shien, Y. Tay, and C. Prives p53 accumulates but is functionally impaired when DNA synthesis is blocked Proc Natl Acad Sci USA 98 2001 1036 1041
11. D.A. Haas-Kogan, G. Yount, and M. Haas p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma Int J Radiat Oncol Biol Phys 36 1996 95 103
12. D.A. Haas-Kogan, S.S. Kogan, and G. Yount p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors Int J Radiat Oncol Biol Phys 43 1999 399 403
13. T.J. Herzog Update on the role of topotecan in the treatment of recurrent ovarian cancer Oncologist 7 2002 3 10
14. Y.H. Hsiang, M.G. Lihou, and L.F. Liu Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin Cancer Res 49 1989 5077 5082
15. J.R. Jackson, A. Gilmartin, C. Imburgia, J.D. Winkler, L.A. Marshall, and A. Roshak An indocarbazole inhibitor of human checkpoint kinase (chk1) abrogates cell cycle arrest caused by DNA damage Cancer Res 60 2000 566 572
16. A.S. Jaiswal, and S. Narayan DNA alkylation-induced phosphorylation of p53 and activation of kinases in colon cancer cells Int J Oncol 19 2001 613 616
17. A.S. Jaiswal, and S. Narayan SN2 DNA alkylating agent-induced phosphorylation of 53 and activation of p21 gene expression Mutat Res 500 2002 17 30
18. A.K. Larsen, and C. Gobert DNA topoisomerase I in oncology: Dr. Jekyll or Mr Hyde? Pathol Oncol Res 5 1999 171 178
19. R.B. Lock, and W.E. Ross DNA topoisomerases in cancer therapy Anticancer Drug Des 2 1987 151 164
20. Y. Mao, S. Okada, L.S. Chang, and M.T. Muller p53 dependence of topoisomerase I recruitment in vivo Cancer Res 60 2000 4538 4543
21. L.D. Mayo, J.E. Dixon, D.L. Durden, N.K. Tonks, and D.B. Donner PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy J Biol Chem 277 2002 5484 5489
22. T.S. Mok, H. Wong, and B. Zee A phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma Cancer 95 2002 1511 1519
23. P.A. Ohneseit, A. Wildemann, C. Herskind, M. Bamberg, and H.P. Rodemann Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation Int J Radiat Biol 78 2002 125 132
24. M. Park, H.D. Chae, J. Yun, Y.-S. Kim, M.H. Han, and D.Y. Shin Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest Cancer Res 60 2000 542 545
25. N. Pore, S. Liu, D.A. Haas-Kogan, D.M. O'Rourke, and A. Maity PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter Cancer Res 63 2003 236 241
26. R.G. Shao, C.X. Cao, T. Shimizu, P.M. O'Connor, K.W. Kohn, and Y. Pommier Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function Cancer Res 57 1997 4029 4035
27. K. Soe, H. Hartmann, B. Schlott, T. Stevnsner, and F. Grosse The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro Oncogene 21 2002 6614 6623
28. K. Soe, and F. Grosse TP53 stimulates human topoisomerase I activity by modulating its DNA binding Nucleic Acids Res 31 2003 6585 6592
29. W.R. Taylor, and G.R. Stark Regulation of the G2/M transition by p53 Oncogene 20 2001 1803 1815
30. H. Ulukan, and P.W. Swaan Camptothecins: a review of their chemotherapeutic potential Drugs 62 2002 2039 2057